13 completed. 9 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 9 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow BMS 181339: new trials by email Literature Review of BMS 181339 trials Research Report on BMS 181339
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin Paclitaxel, Carboplatin, Ipilimumab - Lung Cancer (NSCLC) | Phase 3 | Completed | Bristol-Myers Squibb | 342 | 2014-10-13 | 2019-08-28 |
| Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors BMS-754807, Paclitaxel, Carboplatin - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Completed | Bristol-Myers Squibb | 21 | 2009-04-01 | 2012-07-13 |
| Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine Ipilimumab, Carboplatin, Paclitaxel - Advanced Melanoma | Phase 1 | Completed | Bristol-Myers Squibb | 72 | 2009-02-01 | 2014-01-06 |
| A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer Ixabepilone, 32 mg/m^2, Paclitaxel, 200 mg/m^2, Carboplatin (area under the concentration curve [AUC] 6) - Advanced/Metastatic Non-Small Cell Lung Cancer | Phase 2 | Completed | R-Pharm | 260 | 2008-12-01 | 2020-10-28 |
| Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer Paclitaxel - Esophageal Cancer | Phase 2 | Completed | Bristol-Myers Squibb | 1 | 2008-03-01 | 2013-07-26 |
| A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg, Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg, Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg - Metastatic Breast Cancer | Phase 2 | Completed | R-Pharm | 136 | 2007-03-01 | 2016-03-10 |
| Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer Paclitaxel - Head and Neck Cancer | Phase 2 | Completed | Bristol-Myers Squibb | 11 | 2006-08-04 | 2022-04-08 |
| Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy Alvespimycin, Trastuzumab, Paclitaxel - Solid Tumor, Breast Cancer | Phase 1 | Completed | Bristol-Myers Squibb | 29 | 2006-01-01 | 2011-06-27 |
| Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer Paclitaxel - Head and Neck Cancer | Phase 2 | Completed | Bristol-Myers Squibb | 36 | 2005-10-01 | 2010-02-04 |
| Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer Paclitaxel - Breast Cancer | Phase 2 | Completed | Bristol-Myers Squibb | 6 | 2005-06-30 | 2021-05-25 |
| Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer Paclitaxel - Head and Neck Cancer | Phase 2 | Completed | Bristol-Myers Squibb | 36 | 2004-01-01 | 2011-04-25 |
| Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC) Paclitaxel - Non-Small Cell Lung Cancer | Phase 2 | Completed | Bristol-Myers Squibb | 60 | 2002-12-01 | 2011-04-25 |
| Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer Paclitaxel - Breast Cancer | Phase 2 | Completed | Bristol-Myers Squibb | 68 | 2002-10-01 | 2010-02-04 |
Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Head and Neck Neoplasms (3) · Esophageal Neoplasms (1) · Lung Neoplasms (1) · Neoplasms (1)
Bristol-Myers Squibb (11) · R-Pharm (2)
United States (4) · South Korea (3) · Australia (2) · France (2) · Germany (2) · Italy (2) · Japan (2) · Spain (2) · Argentina (1) · Canada (1) · China (1) · Hungary (1) · Poland (1) · Russia (1) · Singapore (1)
2014 (1)